211,873 Shares in Elanco Animal Health Incorporated $ELAN Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

Posted by Francis Steltz on Sep 9th, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the second quarter, HoldingsChannel.com reports. The firm bought 211,873 shares of the company’s stock, valued at approximately $5,214,000.

Other hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Elanco Animal Health during the 1st quarter worth about $2,065,000. Goldman Sachs Group Inc. grew its holdings in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Empowered Funds LLC grew its holdings in Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after buying an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after buying an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after buying an additional 295,651 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on ELAN. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. Morgan Stanley increased their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Finally, UBS Group raised their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Check Out Our Latest Analysis on Elanco Animal Health

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, insider Shiv O’Neill purchased 3,998 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the purchase, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This represents a 4.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence Kurzius purchased 40,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the purchase, the director directly owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 63,198 shares of company stock valued at $1,473,109 over the last 90 days. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Trading Down 2.3%

Elanco Animal Health stock opened at $23.95 on Wednesday. The business has a 50 day moving average price of $24.63 and a two-hundred day moving average price of $23.96. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The stock has a market cap of $11.96 billion, a price-to-earnings ratio of -58.41, a price-to-earnings-growth ratio of 1.83 and a beta of 1.68. Elanco Animal Health Incorporated has a 12 month low of $18.22 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.Elanco Animal Health’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.